Welcome to our dedicated page for Neurobo Pharmaceuticals SEC filings (Ticker: NRBO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NRBO SEC filings page aggregates the regulatory history of NeuroBo Pharmaceuticals, Inc., which has transitioned to MetaVia Inc., a clinical-stage biotechnology company focused on cardiometabolic diseases. Through these filings, investors can trace how the company reports its progress on DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH), along with key corporate actions.
Recent Forms 8-K filed under the MetaVia Inc. name document material events such as press releases on clinical trial developments for DA-1726, including extensions of multiple ascending dose cohorts, and collaborations to optimize DA-1241 using artificial intelligence–driven drug discovery. Other 8-K filings describe financial results releases and updated corporate presentations, providing insight into the company’s operating progress and communication with the market.
Filings also capture corporate governance and capital structure decisions. For example, an 8-K describing the annual meeting of stockholders details votes on director elections, ratification of the independent registered public accounting firm, advisory approval of executive compensation, authorization of a reverse stock split within a specified ratio range, and approval of share issuances related to financing arrangements.
On Stock Titan, these SEC documents are available with AI-powered summaries that explain the key points of each filing in accessible language. Users can quickly understand the implications of MetaVia’s current reports, including 8-K disclosures on clinical, financial, and governance matters, and navigate the historical record associated with the NRBO ticker as the company continues under the MetaVia identity.